Long-Term Results of Monoclonal Anti-Il2-Receptor Antibody Versus Polyclonal Antilymphocyte Antibodies as Induction Therapy in Renal Transplantation

Transplantation Proceedings

Volumn 38, Issue 7, 2006, Pages 2298-2299

  Al Najjar, A ^a   Etienne, I ^b   Le Pogamp, P ^c   Bridoux, F ^d   Le Meur, Y ^e   Toupance, O ^f   Mousson, C ^g   Caillard, S ^h   de Ligny, B Hurault ⁱ   Marliere J F ^a   Lebranchu, Y ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁱ CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; PROTEIN; STEROID;

ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STEROID THERAPY;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS;

EID: 33846079180     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.06.133     Document Type: Article

References (4)

1. Lebranchu Y., Bridoux F., and Buchler M. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2 (2002) 48
2. Mourad G., Rostaing L., and Legendre C. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584
3. Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant 9 (2005) 373
4. Haririan A., Morawski K., and Sillix D.H. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 79 (2005) 716